Screening study of mismatch repair (MMR) protein and BRAF mutant protein for rectal cancer

Screening study of mismatch repair (MMR) protein and BRAF mutant protein for rectal cancer - R-MMR research

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050759

Enrollment

1000

Registered

2023-05-01

Start date

2023-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer confirmed by histopathological diagnosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Rectal cancer confirmed by histopathological diagnosis. 2) Age is 18 years or older. 3) IHC tests to detect MMR protein and tests to detect BRAF mutations (PCR test or IHC test) were performed in the clinical practice.

Exclusion criteria

Exclusion criteria: 1)Cases judged to be unsuitable for enrollment in this study. 2)Patients who have requested that they do not wish to participate in the study.

Design outcomes

Primary

Measure	Time frame
Frequency of dMMR in rectal cancer specimens, loss of expression frequency of each MMR protein (MLH1, PMS2, MSH2, MSH6), frequency of BRAF V600E mutation	—

Secondary

Measure	Time frame
Associations between MMR, BRAF V600E mutation status and patient background factors	—

Countries

Japan

Contacts

Public ContactYu Miyashita

National Cancer Center Hospital East Gastrointestinal internal medicine

yumiyash@east.ncc.go.jp04-7133-1111

Outcome results